Details of the Drug Combinations

General Information of This Drug (ID: DMUKC5L)

Drug Name

Tivozanib DMUKC5L

Synonyms

ASP4130/AV-951

Indication

Disease Entry	ICD 11	Status	REF
Renal cell carcinoma	2C90	Approved	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

4 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Erlotinib + Tivozanib	DCPSAAG	Erlotinib	Non-small Cell Lung Cancer	[2]
Everolimus + Tivozanib	DCEFV5W	Everolimus	Gastrointestinal Cancer	[3]
Enzalutamide + Tivozanib	DC5MYIG	Enzalutamide	Prostate Cancer	[4]
Gemcitabine + Tivozanib	DCPWF2J	Gemcitabine	Renal Cell Carcinoma	[5]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
2	ClinicalTrials.gov (NCT01728181) A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat Serum Proteomic Evaluation
3	ClinicalTrials.gov (NCT01058655) RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
4	ClinicalTrials.gov (NCT01885949) Tivozanib + Enzalutamide in Adv Prostate Cancer
5	ClinicalTrials.gov (NCT01834183) Tivozanib + Gemcitabine in Metastatic RCC